Table 1.
Tumor, patient and treatment characteristics
| Characteristic | Overall population (N = 230) |
|---|---|
| Age (years) – median (range) | 62 (35-95) |
| BMI – median (range) | 25.3 (17.2-48.8) |
| Underweight/normal | 103 (45.4%) |
| Overweight | 76 (33.5%) |
| Obese | 48 (21.1%) |
| Menopausal status | |
| Premenopausal | 49 (21.3%) |
| Postmenopausal | 181 (78.7%) |
| Tumor histology | |
| NST | 200 (87.0%) |
| ILC | 21 (9.1%) |
| Other | 9 (3.9%) |
| Histological grade | |
| 1 | 97 (42.1%) |
| 2 | 120 (52.5%) |
| 3 | 7 (3.0%) |
| Unknown | 6 (2.6%) |
| Clinical T stage | |
| 1 | 172 (74.8%) |
| 2 | 50 (21.7%) |
| 3 | 6 (2.6%) |
| 4 | 2 (0.9%) |
| Clinical N stage | |
| N0 | 222 (96.5%) |
| N1 | 6 (2.6%) |
| Nx | 2 (0.9%) |
| Baseline Ki67 results – median (range) | 12 (1-80) |
| ≤10% | 102 (44.3%) |
| 11%-29% | 100 (43.5%) |
| ≥30% | 28 (12.2%) |
| Baseline ER status | |
| 1%-10% | 2 (0.9%) |
| ≥10% | 228 (99.1%) |
| Baseline PR status | |
| <10% | 32 (13.9%) |
| ≥10% | 198 (86.1%) |
| ET duration (weeks) – median (range) | 5 (2-12) |
| Endocrine treatment | |
| TAM | 57 (24.8%) |
| AI | 173 (75.2%) |
| Postsurgical Ki67 results – median (range) | 3 (1-75) |
| ≤10% | 196 (85.2%) |
| 11%-29% | 27 (11.7%) |
| ≥30% | 7 (3.0%) |
| Pathological T stage | |
| 1 | 180 (78.6%) |
| 2 | 43 (18.8%) |
| 3 | 5 (2.2%) |
| 4 | 1 (0.4%) |
| Unknown | 1 |
| Pathological N stage | |
| N0 | 160 (73.1%) |
| N1 | 52 (23.6%) |
| N2 | 6 (2.7%) |
| N3 | 1 (0.5%) |
| Unknown | 11 |
| Adjuvant chemotherapy | |
| Yes | 51 (22.2%) |
| No | 178 (77.4%) |
| Unknown | 1 (0.4%) |
AI, aromatase inhibitor; BMI, body mass index; ER, estrogen receptor; ET, endocrine therapy; ILC, invasive lobular carcinoma; NST, no special type; PR, progesterone receptor; TAM, tamoxifen.